A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib NSC-763760 and Trametinib NSC-763093 in BRAFV600E/K Mutant Melanoma
A Phase I/II Study of Pembrolizumab MK-3475 in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma KEYNOTE-051
A PHASE II RANDOMIZED STUDY OF NIVOLUMAB (NSC-748726) WITH IPILIMUMAB (NSC-732442) OR IPILIMUMAB ALONE IN ADVANCED MELANOMA PATIENTS
REFRACTORY TO AN ANTI-PD1 OR ANTI-PD-L1 AGENT
Randomized Phase II/III Study Of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab In Patients With Unresectable State III Or Stage IV Melanoma
A Phase III, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and
Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection
of Stage III-IV Melanoma
MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations Excluding Melanoma and Thyroid Cancer
A Phase II Study of Brentuximab Vedotin in Combination with Checkpoint Inhibitor CPI Therapy in Subjects with Metastatic Solid Tumors After Progression on Prior PD-1 Inhibitor Treatment
A Phase II Study of Combining T-VEC NSC-785349 and Pembrolizumab NSC-776864 in Patients with Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
Phase I/II Open-Label Study to Evaluate the Safety and Preliminary Efficacy of Mrx0518 in Combination with Pembrolizumab in Patients with Non-Small-Cell Lung Cancer, Renal Cell Carcinoma, Bladder Cancer, and Melanoma Who Have Progressed on PD-1 Inhibitors